Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

An overview of PROTACs: a promising drug discovery paradigm
Liu Zi, Mingxing Hu, Yang Yu, et al.
Molecular Biomedicine (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 147

Showing 1-25 of 147 citing articles:

The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods
Barbara Zdrazil, Eloy Félix, Fiona Hunter, et al.
Nucleic Acids Research (2023) Vol. 52, Iss. D1, pp. D1180-D1192
Open Access | Times Cited: 326
Exploring the next generation of antibody–drug conjugates
Kyoji Tsuchikama, Yasuaki Anami, Summer Y. Y. Ha, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 3, pp. 203-223
Open Access | Times Cited: 172
Targeted protein degradation: from mechanisms to clinic
Jonathan M. Tsai, Radosław P. Nowak, Benjamin L. Ebert, et al.
Nature Reviews Molecular Cell Biology (2024) Vol. 25, Iss. 9, pp. 740-757
Closed Access | Times Cited: 87
Targeted protein degrader development for cancer: advances, challenges, and opportunities
Yuan Fang, Shuhang Wang, Songzhe Han, et al.
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 5, pp. 303-317
Open Access | Times Cited: 44
Roles and inhibitors of FAK in cancer: current advances and future directions
Hui-Hui Hu, Saiqi Wang, Hai-Li Shang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 24
Characteristic roadmap of linker governs the rational design of PROTACs
Yawen Dong, Tingting Ma, Ting Xu, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 10, pp. 4266-4295
Open Access | Times Cited: 22
Revolutionizing Cancer Treatment: Unleashing the Power of Viral Vaccines, Monoclonal Antibodies, and Proteolysis-Targeting Chimeras in the New Era of Immunotherapy
Popat Mohite, Vaishnavi Yadav, Ramdas Pandhare, et al.
ACS Omega (2024)
Open Access | Times Cited: 16
Multicomponent reactions (MCRs) yielding medicinally relevant rings: a recent update and chemical space analysis of the scaffolds
Mukesh Tandi, Vaibhav Sharma, B. Gopal, et al.
RSC Advances (2025) Vol. 15, Iss. 2, pp. 1447-1489
Open Access | Times Cited: 2
Targeted Protein Degradation: Advances, Challenges, and Prospects for Computational Methods
Barmak Mostofian, Holli‐Joi Martin, Asghar M. Razavi, et al.
Journal of Chemical Information and Modeling (2023) Vol. 63, Iss. 17, pp. 5408-5432
Open Access | Times Cited: 27
Research in the Field of Drug Design and Development
Grażyna Biała, Ewa Kędzierska, Marta Kruk-Słomka, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 9, pp. 1283-1283
Open Access | Times Cited: 27
PROTACs: A novel strategy for cancer drug discovery and development
Xin Han, Yi Sun
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 24
Pre-mRNA splicing-associated diseases and therapies
Sierra L. Love, Joseph D. Emerson, Kazunori Koide, et al.
RNA Biology (2023) Vol. 20, Iss. 1, pp. 525-538
Open Access | Times Cited: 23
Anticancer drugs: How to select small molecule combinations?
Ruth Nussinov, Bengi Ruken Yavuz, Hyunbum Jang
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 6, pp. 503-519
Closed Access | Times Cited: 13
Targeted protein degradation: advances in drug discovery and clinical practice
Guangcai Zhong, Xiaoyu Chang, Weilin Xie, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 13
Protein tyrosine phosphatase 1B in metabolic diseases and drug development
Mirela Delibegović, Sergio Dall’Angelo, Ruta Dekeryte
Nature Reviews Endocrinology (2024) Vol. 20, Iss. 6, pp. 366-378
Closed Access | Times Cited: 10
Repurposing AS1411 for constructing ANM-PROTACs
Xuekun Fu, Jin Li, Xinxin Chen, et al.
Cell chemical biology (2024) Vol. 31, Iss. 7, pp. 1290-1304.e7
Closed Access | Times Cited: 10
Recent Advances on Targeting Proteases for Antiviral Development
Pedro Henrique Oliveira Borges, Sabrina Baptista Ferreira, Floriano Paes Silva
Viruses (2024) Vol. 16, Iss. 3, pp. 366-366
Open Access | Times Cited: 9
PROTACs targeting androgen receptor signaling: Potential therapeutic agents for castration-resistant prostate cancer
Yulu Zhang, Annan Ming, Junyan Wang, et al.
Pharmacological Research (2024) Vol. 205, pp. 107234-107234
Open Access | Times Cited: 8
PROTACs in the treatment of viral diseases
Ritesh Bhole, Payal R. Kute, Shailendra Gurav
Future Medicinal Chemistry (2025) Vol. 17, Iss. 3, pp. 267-269
Closed Access | Times Cited: 1
PROTAC-induced Protein Structural Dynamics in Targeted Protein Degradation
Kingsley Y Wu, Ta I Hung, Chia‐en A. Chang
(2025)
Open Access | Times Cited: 1
Drug Discovery Targeting Nuclear Receptor Binding SET Domain Protein 2 (NSD2)
Zonghui Ma, Andrew A. Bolinger, Haiying Chen, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 16, pp. 10991-11026
Open Access | Times Cited: 20
Revolutionizing Drug Targeting Strategies: Integrating Artificial Intelligence and Structure-Based Methods in PROTAC Development
Mohd Danishuddin, Mohammad Sarwar Jamal, Kyoung Seob Song, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 12, pp. 1649-1649
Open Access | Times Cited: 17
Progress in the controllability technology of PROTAC
Xin He, Zhibing Weng, Yi Zou
European Journal of Medicinal Chemistry (2023) Vol. 265, pp. 116096-116096
Closed Access | Times Cited: 17
Novel Amphiphilic PROTAC with Enhanced Pharmacokinetic Properties for ALK Protein Degradation
Shirui Wang, Zhanzhan Feng, Can Qu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 12, pp. 9842-9856
Closed Access | Times Cited: 7
Selective degradation of hyperphosphorylated tau by proteolysis-targeting chimeras ameliorates cognitive function in Alzheimer’s disease model mice
Dongping Yao, Ting Li, Lu Yu, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top